News | May 07, 2026
Novo Nordisk posts strong Q1 as Wegovy drives global GLP-1 momentum
The standout story remains Wegovy, particularly its new oral formulation
The standout story remains Wegovy, particularly its new oral formulation
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
The company’s Growth Portfolio delivered $6.2 billion in revenue
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Subscribe To Our Newsletter & Stay Updated
